

Worldwide Sales

\$2.7B

 **8% Reported Basis**
 **3% Operational Basis¹**

Adjusted Earnings Per Diluted Share¹ \$0.70  **21%**

Increased Full-Year 2018 Financial Outlook
vs. Guidance Issued Feb. 1, 2018

Reported Basis



vs. Original Sales Guidance of 6-7%

Operational Basis¹



vs. Original Sales Guidance of 4%

Adjusted Earnings Per Diluted Share¹

\$2.85 - \$2.93

Increased on Both Ends of Range



"Baxter is off to a strong start in 2018. Solid top-line performance coupled with a relentless focus on increasing operational efficiency were key drivers of earnings growth in the quarter."

José (Joe) E. Almeida, Chairman and Chief Executive Officer

Global Business Units: 1Q18 Revenue and Operational Growth¹

RENAL CARE



\$868M
+4%

MEDICATION DELIVERY



\$676M
+0%

PHARMACEUTICALS



\$496M
+6%

NUTRITION



\$223M
+0%

ADVANCED SURGERY



\$182M
+4%

ACUTE THERAPIES



\$129M
+14%

¹ Visit www.baxter.com for information regarding non-GAAP financial metrics used here, including operational sales and adjusted earnings per share.